ICCM Aperçu des actions IceCure Medical Ltd, une société de dispositifs médicaux en phase commerciale, se consacre à la recherche, au développement et à la commercialisation de systèmes de cryoablation, de produits jetables et de technologies pour le traitement des tumeurs. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
IceCure Medical Ltd Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 IceCure Medical Historique des cours de bourse Prix actuel de l'action US$1.30 Plus haut sur 52 semaines US$1.46 Plus bas sur 52 semaines US$0.48 Bêta 2.58 Variation sur 1 mois -0.38% Variation sur 3 mois 120.30% Variation sur 1 an -6.47% Variation sur 3 ans -50.00% Variation sur 5 ans 381.48% Évolution depuis l'introduction en bourse 1,110.43%
Nouvelles et mises à jour récentes
IceCure Medical Ltd. Files for Regulatory Approval of ProSense Cryoablation System in China Jan 27 IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $13.9605 million. Jan 13
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office Jan 03
Less than half of directors are independent Jan 02
IceCure Medical Ltd Appoints Li Haixiang as Director Jan 01
IceCure Medical Ltd. Announces Data from its ICE3 Trial of ProSense®? in Early-Stage Breast Cancer Dec 16 Voir plus de mises à jour
IceCure Medical Ltd. Files for Regulatory Approval of ProSense Cryoablation System in China Jan 27 IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $13.9605 million. Jan 13
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office Jan 03
Less than half of directors are independent Jan 02
IceCure Medical Ltd Appoints Li Haixiang as Director Jan 01
IceCure Medical Ltd. Announces Data from its ICE3 Trial of ProSense®? in Early-Stage Breast Cancer Dec 16
IceCure Medical Ltd. Announces Interim Results from the ICESECRET Study of Cryoablation for Patients with Small Renal Masses Dec 05
Consensus revenue estimates fall by 13% Dec 03
No longer forecast to breakeven Nov 27
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 26
IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024 Nov 20 IceCure Medical Ltd has filed a Follow-on Equity Offering. Oct 16
IceCure Medical Ltd. Announces Study Publishes in British Journal of Radiology Demonstrates IceCure's ProSense is Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of Lung, Bone, and Soft Tissues Sep 16
IceCure Medical Ltd. Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 Sep 12
U.S. Patent and Trademark Office Grants Notice of Allowance for Additional Patent on IceCure Medical Ltd.'s Novel Cryogenic Pump Technology Aug 29
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 21
Forecast to breakeven in 2026 Aug 21
IceCure Medical Ltd Announces the Publication of an Independent Study of Patients Who Chose Cryoablation for the Treatment of Early Breast Cancer in Non-Surgical Patients Aug 15
IceCure Medical Ltd to Report Q2, 2024 Results on Aug 20, 2024 Aug 13
IceCure Medical Ltd. Announces Positive Data from the Largest Multi-Institutional Study of Its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials Aug 08
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth? Jul 31
New minor risk - Share price stability Jul 23
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification Jul 23
IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense Jul 10
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes Jul 02
New minor risk - Shareholder dilution Jun 13
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025 Jun 06
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 30
IceCure Medical Ltd to Report Q1, 2024 Results on May 28, 2024 May 23
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound–Guided Cryoablation for Early–Stage Primary Breast Cancer: A Follow–Up Study in Japan," in the Journal Breast Cancer on April 27, 2024 May 08 IceCure Medical Ltd, Annual General Meeting, May 20, 2024
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 03
Icecure Submits FDA Regulatory Filing for New Xsense™ Cryoablation System with Cryoprobes Apr 02
IceCure Medical Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024 Mar 28
Price target increased by 14% to US$3.33 Mar 20
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study Mar 20
IceCure Medical Ltd. Announces Results from an Independent Study Mar 06
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study Feb 27
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company’s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda’S Prior Denial of Icecure’S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer Jan 30
IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $9.7 million. Jan 14 IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Forecast to breakeven in 2026 Dec 31
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients Dec 13
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense Nov 29
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate Nov 29
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer Nov 17
IceCure Medical Ltd to Report Q3, 2023 Results on Nov 15, 2023 Nov 09
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System Nov 08
New major risk - Revenue and earnings growth Sep 21
IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer Sep 21
Price target decreased by 15% to US$3.41 Sep 20
Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil Sep 07
Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil Sep 06
Second quarter 2023 earnings: EPS misses analyst expectations Aug 16
IceCure Medical Ltd to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans? Aug 08
Health Canada Approves Icecure Medical's Minimally Invasive Prosense Cryoablation System Jul 25
New major risk - Financial position Jul 05
New major risk - Revenue and earnings growth Jun 29
IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023 May 16
Insufficient new directors May 01
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Mar 31
Price target decreased by 14% to US$3.96 Mar 22
IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump Jan 24
IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems Jan 19
IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses Dec 21
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors Dec 07
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Dec 05
IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022 Nov 29
Price target decreased to US$4.58 Nov 16
IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures Nov 09
Price target decreased to US$4.58 Oct 25
IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery Oct 20
IceCure gains 19% on seeking FDA nod for cancer treatment Oct 19
IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense® Aug 30
Second quarter 2022 earnings released Aug 17
IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022 Aug 10
IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors Jul 26
IceCure files application for approval of ProSense in Canada for tumors Jul 25
IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022 May 12
Price target decreased to US$7.58 Apr 27
Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020) Apr 02
Now 25% undervalued after recent price drop Feb 09
IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022 Jan 28
IceCure Medical: Advancing Cryotherapy For Cancer Treatment Jan 25
Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump Dec 22
IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America Dec 03
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Nov 26
First half 2021 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1H 2020) Sep 29
Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer Sep 14
Icecure Medical Ordinary Shares Deleted from Other OTC Aug 27
IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting May 05
IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East Feb 18 Rendement pour les actionnaires ICCM US Medical Equipment US Marché 7D 3.2% 0.4% 1.2% 1Y -6.5% 13.3% 21.0%
Voir le rapport complet des actionnaires
Rendement vs Industrie: ICCM a sous-performé le secteur US Medical Equipment qui a rapporté 13.3 % au cours de l'année écoulée.
Rendement vs marché: ICCM a sous-performé le marché US qui a rapporté 21 % au cours de l'année écoulée.
Volatilité des prix Is ICCM's price volatile compared to industry and market? ICCM volatility ICCM Average Weekly Movement 10.9% Medical Equipment Industry Average Movement 8.1% Market Average Movement 6.0% 10% most volatile stocks in US Market 18.5% 10% least volatile stocks in US Market 3.0%
Cours de l'action stable: Le cours de l'action de ICCM a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ICCM ( 11% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise IceCure Medical Ltd, une société de dispositifs médicaux en phase commerciale, se consacre à la recherche, au développement et à la commercialisation de systèmes de cryoablation, de produits jetables et de technologies pour le traitement des tumeurs. La société propose le système ProSense, un système à sonde unique pour le traitement des tumeurs, ainsi que les produits jetables associés, et le système IceSense3 pour les indications d'ablation en urologie, oncologie, dermatologie, gynécologie, chirurgie générale, chirurgie thoracique et proctologie. Elle développe également le système XSense, un système à sonde unique, et le système MultiSense, un système à sondes multiples pour le traitement des tumeurs multiples et de grande taille.
Afficher plus IceCure Medical Ltd Résumé des fondamentaux Comment les bénéfices et les revenus de IceCure Medical se comparent-ils à sa capitalisation boursière ? ICCM statistiques fondamentales Capitalisation boursière US$72.41m Bénéfices(TTM) -US$13.83m Recettes(TTM ) US$3.67m
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) ICCM compte de résultat (TTM ) Recettes US$3.67m Coût des recettes US$2.07m Marge brute US$1.60m Autres dépenses US$15.44m Les revenus -US$13.83m
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -0.24 Marge brute 43.67% Marge bénéficiaire nette -376.85% Ratio dettes/capitaux propres 0%
Quelles ont été les performances à long terme de ICCM?
Voir les performances historiques et les comparaisons
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2025/02/10 07:49 Cours de l'action en fin de journée 2025/02/10 00:00 Les revenus 2024/09/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github .
Sources des analystes IceCure Medical Ltd est couverte par 3 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Brian Kemp Dolliver Brookline Capital Markets Yi Chen H.C. Wainwright & Co. Anthony Vendetti Maxim Group
